Insider Selling: Hikma Pharmaceuticals PLC (LON:HIK) Insider Sells 13,863 Shares of Stock

Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) insider Said Darwazah sold 13,863 shares of the company's stock in a transaction on Friday, May 30th. The stock was sold at an average price of GBX 2,138 ($28.97), for a total value of £296,390.94 ($401,668.17).

Hikma Pharmaceuticals Stock Performance

Shares of Hikma Pharmaceuticals stock traded down GBX 27.35 ($0.37) during trading on Wednesday, reaching GBX 2,102.66 ($28.50). The company's stock had a trading volume of 443,765 shares, compared to its average volume of 1,287,854. Hikma Pharmaceuticals PLC has a one year low of GBX 1,751 ($23.73) and a one year high of GBX 2,360 ($31.98). The firm has a market cap of £5.83 billion, a price-to-earnings ratio of 20.63, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41. The business's fifty day moving average price is GBX 1,969.65 and its 200-day moving average price is GBX 2,040.33. The company has a debt-to-equity ratio of 55.82, a quick ratio of 1.27 and a current ratio of 1.66.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on HIK shares. JPMorgan Chase & Co. restated an "overweight" rating on shares of Hikma Pharmaceuticals in a research note on Friday, March 7th. Berenberg Bank restated a "buy" rating and issued a GBX 2,560 ($34.69) target price on shares of Hikma Pharmaceuticals in a research report on Monday, March 10th.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.